Top

Published in:

01-06-2020

Oleic Acid Protects from Arsenic-Induced Cardiac Hypertrophy via AMPK/FoxO/NFATc3 Pathway

Authors: Jayeeta Samanta, Arunima Mondal, Srimoyee Saha, Santanu Chakraborty, Arunima Sengupta

Published in: Cardiovascular Toxicology | Issue 3/2020

Abstract

Arsenic toxicity is one of the major environmental problems causing various diseases, cardiovascular disorders is one of them. Several epidemiological studies have shown that arsenic causes cardiac hypertrophy but the detailed molecular mechanism is to be studied yet. This study is designed to determine the molecules involved in the augmentation of arsenic-induced cardiac hypertrophy. Furthermore, the effects of oleic acid on arsenic-induced hypertrophy and cardiac injury have also been investigated. Our results show that arsenic induces cardiac hypertrophy both in vivo in mice and in vitro in rat H9c2 cardiomyocytes. Moreover, arsenic results in decreased activity of AMPK and FoxO1 along with increased NFATc3 expression, a known cardiac hypertrophy inducer. In addition, activation of AMPK and FoxO1 results in reduced NFATc3 expression causing attenuation of arsenic-induced cardiac hypertrophy in H9c2 cells. Interestingly, we have observed that oleic acid helps in ameliorating cardiac hypertrophy in arsenic-exposed mice. Our studies on protection from arsenic-induced cardiac hypertrophy by oleic acid in H9c2 cells shows that oleic acid activates AMPK along with increased nuclear FoxO1 localization, thereby reducing NFATc3 expression and attenuating cardiomyocyte hypertrophy. This study will help in finding out new avenues in treating arsenic-induced cardiac hypertrophy.

Available only for authorised users

Al-Shudiefat, A. A. R., Sharma, A. K., Bagchi, A. K., Dhingra, S., & Singal, P. K. (2013). Oleic acid mitigates TNF-a-induced oxidative stress in rat cardiomyocytes. Molecular and Cellular Biochemistry,372, 75–82.PubMedCrossRef

Bairwa, S. C., Parajuli, N., & Dyck, J. R. B. (2016). The role of AMPK in cardiomyocyte health and survival. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease,1862(12), 2199–2210.CrossRef

Beauchamp, E. M., Kosciuczuk, E. M., Serrano, R., Nanavati, D., Swindell, E. P., Viollet, B., et al. (2015). Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors. Molecular Cancer Therapeutics,14(1), 202–212.PubMedCrossRef

Bhattacharya, S. (2016). Medicinal plants and natural products in amelioration of arsenic toxicity: A short review. Pharmaceutical Biology,55(1), 349–354.PubMedCentralCrossRef

Chan, A. Y. M., Dolinsky, V. W., Soltys, C. L. M., Viollet, B., Baksh, S., Light, P. E., et al. (2008). Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. The Journal of Biological Chemistry,283, 24194–24201.PubMedPubMedCentralCrossRef

Chan, A. Y., Soltys, C. L., Young, M. E., Proud, C. G., & Dyck, J. R. (2004). Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. Journal of Biological Chemistry,279, 32771–32779.PubMedCrossRef

Divya, S. P., Pratheeshkumar, P., Son, Y. O., Roy, R. V., Hitron, J. A., Kim, D., et al. (2015). Arsenic induces insulin resistance in mouse adipocytes and myotubes via oxidative stress-regulated mitochondrial Sirt3-FOXO3a signaling pathway. Toxicological Sciences,146(2), 290–300.CrossRef

Ellinsworth, D. C. (2015). Arsenic, reactive oxygen, and endothelial dysfunction. Journal of Pharmacology and Experimental Therapeutics,353(3), 458–464.PubMedCrossRef

Fan, Y., Wang, C., Zhang, Y., Hang, P., Liu, Y., Pan, Z., et al. (2013). Genistein ameliorates adverse cardiac effects induced by arsenic trioxide through preventing cardiomyocytes apoptosis. Cellular Physiology and Biochemistry,31, 80–91.PubMedCrossRef

10.

Firdaus, F., Zafeer, M. F., Ahmad, M., & Afzal, M. (2018). Anxiolytic and anti-inflammatory role of thymoquinone in arsenic-induced hippocampal toxicity in Wistar rats. Heliyon,4(6), e00650.PubMedPubMedCentralCrossRef

11.

Gonçalves-de-Albuquerque, C. F., Medeiros-de-Moraes, I. M., Oliveira, F. M. J., Burth, P., Bozza, P. T., Faria, M. V. C., et al. (2016). Omega-9 oleic acid induces fatty acid oxidation and decreases organ dysfunction and mortality in experimental sepsis. PLos ONE,11(4), 153607.CrossRef

12.

Hamann, I., Petroll, K., Hou, X., Anwar-Mohamed, A., El-Kadi, A. O., & Klotz, L. O. (2014). Acute and long-term effects of arsenite in HepG2 cells: Modulation of insulin signaling. BioMetals,27(2), 317–332.PubMedCrossRef

13.

Herum, K. M., Lunde, I. G., Skrbic, B., Florholmen, G., Behmen, D., Sjaastad, I., et al. (2013). Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress. Journal of Molecular and Cellular Cardiology,54, 73–81.PubMedCrossRef

14.

Davis, Jennifer, Burr, Adam R., Davis, Gregory F., Birnbaumer, Lutz, & Molkentin, Jeffery D. (2012). A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Developmental Cell,23(4), 705–715.PubMedPubMedCentralCrossRef

15.

Kris-Etherton, P. M. (1999). Monounsaturated fatty acids and risk of cardiovascular disease. Circulation,100, 1253–1258.PubMedCrossRef

16.

Li, H. L., Yin, R., Chen, D., Liu, D., Wang, D., Yang, Q., et al. (2007). Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. Journal of Cellular Biochemistry,100, 1086–1099.PubMedCrossRef

17.

Liu, B., Pan, S., Dong, X., Qiao, H., Jiang, H., Krissansen, G. W., et al. (2006). Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Science,97, 675–681.PubMedCrossRef

18.

Livingstone, K. M., Lovegrove, J. A., & Givens, D. I. (2012). The impact of substituting SFA in dairy products with MUFA or PUFA on CVD risk: Evidence from human intervention studies. Nutrition Research Reviews,25(2), 193–206.PubMedCrossRef

19.

Manna, P., Sinha, M., & Sil, P. C. (2008). Arsenic-induced oxidative myocardial injury: Protective role of arjunolic acid. Archives of Toxicology,82, 137–149.PubMedCrossRef

20.

Medeiros-de-Moraes, I. M., Gonçalves-de-Albuquerque, C. F., Kurz, R. M. A., Oliveira, F. M. J., Pereira de Abreu, V. H., Torres, R. C., et al. (2018). Omega-9 oleic acid, the main compound of olive oil, mitigates inflammation during experimental sepsis. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2018/6053492.PubMedPubMedCentralCrossRef

21.

Miao, X., Tang, Z., Wang, Y., Su, G., Sun, W., Wei, W., et al. (2013). Metallothionein prevention of arsenic trioxide-induced cardiac cell death is associated with its inhibition of mitogen-activated protein kinases activation in vitro and in vivo. Toxicology Letters,220, 277–285.PubMedCrossRef

22.

Moon, K., Guallar, E., & Navas-Acien, A. (2012). Arsenic exposure and cardiovascular disease: An updated systematic review. Current Atherosclerosis Reports,14(6), 542–555.PubMedPubMedCentralCrossRef

23.

Ni, Y. G., Berenji, K., Wang, N., Oh, M., Sachan, N., Dey, A., et al. (2006). Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation,114(11), 1159–1168.PubMedPubMedCentralCrossRef

24.

Pace, C., Dagda, R., & Angermann, J. (2017). Antioxidants protect against arsenic induced mitochondrial cardio-toxicity. Toxics,5(4), 38.PubMedCentralCrossRef

25.

Phan, N. N., Wang, C. Y., & Lin, Y. C. (2014). The novel regulations of MEF2A, CAMKK2, CALM3, and TNNI3 in ventricular hypertrophy induced by arsenic exposure in rats. Toxicology,324, 123–135.PubMedCrossRef

26.

Li, Qing, Dong, Qiu-Ting, Yang, Yue-Jin, Tian, Xia-Qiu, Jin, Chen, Huang, Pei-Sen, et al. (2016). AMPK-mediated cardioprotection of atorvastatin relates to the reduction of apoptosis and activation of autophagy in infarcted rat hearts. American Journal of Translational Research,8(10), 4160–4171.PubMedPubMedCentral

27.

Roehrl, M. H. A., Kang, S., Aramburu, J., Wagner, G., Rao, A., & Hogan, P. G. (2004). Selective inhibition of calcineurin-NFAT signaling by blocking protein–protein interaction with small organic molecules. PNAS,101(20), 7554–7559.PubMedCrossRef

28.

Rooij, E. V., Doevendans, P. A., Theije, C. C., Babiker, F. A., Molkentin, J. D., & Windt, L. J. D. (2002). Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. Journal of Biological Chemistry,277(50), 48617–48626.PubMedCrossRef

29.

Salvadó, L., Coll, T., Gómez-Foix, A. M., Salmerón, E., Barroso, E., Palomer, X., et al. (2013). Oleate prevents saturated-fatty-acid-induced ER stress, inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia,56, 1372–1382.PubMedCrossRef

30.

Sanchez-Soria, P., Broka, D., Monks, S. L., & Camenisch, T. D. (2012). Chronic low-level arsenite exposure through drinking water increases blood pressure and promotes concentric left ventricular hypertrophy in female mice. Toxicologic Pathology,40(3), 504–512.PubMedPubMedCentralCrossRef

31.

Sengupta, A., Kalinichenko, V. V., & Yutzey, K. E. (2013). FoxO and FoxM1 transcription factors have antagonistic functions in neonatal cardiomyocyte cell cycle withdrawal and IGF1 gene regulation. Circulation Research,112(2), 267–277.PubMedCrossRef

32.

Sengupta, A., Molkentin, J. D., Paik, J. H., Pinho, R. A. D., & Yutzey, K. E. (2011). FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. The Journal of Biological Chemistry,286(9), 7468–7478.PubMedCrossRef

33.

States, J. C., Srivastava, S., Chen, Y., & Barchowsky, A. (2009). Arsenic and cardiovascular disease. Toxicological Sciences,107(2), 312–323.PubMedCrossRef

34.

Tseng, C. H., Chong, C. K., Tseng, C. P., Hsueh, Y. M., Chiou, H. Y., Tseng, C. C., et al. (2003). Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicology Letters,137(1–2), 15–21.PubMedCrossRef

35.

Wang, K., Long, B., Zhou, J., & Li, P. F. (2010). miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. The Journal of Biological Chemistry,285, 11903–11912.PubMedPubMedCentralCrossRef

36.

Wilkins, B. J., De Windt, L. J., Bueno, O. F., Braz, J. C., Glascock, B. J., Kimball, T. F., et al. (2002). Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Molecular and Cellular Biology,22(21), 7603–7613.PubMedPubMedCentralCrossRef

37.

Yu, H., Berkel, T. J. C., & Biessen, E. A. L. (2007). Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders. Cardiovascular Drug Reviews,25(2), 175–187.PubMedCrossRef

38.

Yun, H., Park, S., Kim, M. J., Yang, W. K., Im, D. U., Yang, K. R., et al. (2014). AMP-activated protein kinase mediates the antioxidant effects of resveratrol through regulation of the transcription factor FoxO1. The FEBS Journal,281, 4421–4438.PubMedCrossRef

39.

Zhao, X. Y., Li, G. Y., Liu, Y., Chai, L. M., Chen, J. X., Zhang, Y., et al. (2008). Reseveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. British Journal of Pharmacology,154, 105–113.PubMedPubMedCentralCrossRef

Title: Oleic Acid Protects from Arsenic-Induced Cardiac Hypertrophy via AMPK/FoxO/NFATc3 Pathway
Authors: Jayeeta Samanta
Arunima Mondal
Srimoyee Saha
Santanu Chakraborty
Arunima Sengupta
Publication date: 01-06-2020
Publisher: Springer US
Published in: Cardiovascular Toxicology / Issue 3/2020
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-019-09550-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Oleic Acid Protects from Arsenic-Induced Cardiac Hypertrophy via AMPK/FoxO/NFATc3 Pathway

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Protective Effect of RIVA Against Sunitinib-Induced Cardiotoxicity by Inhibiting Oxidative Stress-Mediated Inflammation: Probable Role of TGF-β and Smad Signaling

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Coenzyme Q10 Cardioprotective Effects Against Doxorubicin-Induced Cardiotoxicity in Wistar Rat

Late-life Cardiac Injury in Rats following Early Life Exposure to Lead: Reversal Effect of Nutrient Metal Mixture

Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice

Vehicular Particulate Matter (PM) Characteristics Impact Vascular Outcomes Following Inhalation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page